UrologyNews.net

Urology Xagena

Studies investigating the association of food and nutrient consumption with the risk of urothelial cell carcinoma ( UCC ) have produced mixed results. Researchers used three common dietary scores, t ...


Little is known about the outcomes and prognostic factors of adjuvant chemotherapy for locally advanced penile squamous cell carcinoma after regional lymphadenectomy ( LAD ). Researchers have retro ...


The efficacy and safety of a combination of chemotherapeutic agent compared with single-agent chemotherapy in the second-line setting of advanced urothelial carcinoma ( UC ) are unclear. Researchers ...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the treatment of people with locally advanced or metastatic urothelial carcinoma ( mUC ...


Ureteral stent-related pain is a well-known side effect of stent placement. To date, there is a paucity of resources that address this topic. Stent pain pathophysiology is multifactorial and likely ...


The results from the STRIVE trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in men with castration-resistant prostate cancer ( CRPC ) are published in the Journal of Clinical Onc ...


The results from the phase 2 TERRAIN trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in metastatic castration-resistant prostate cancer ( CRPC ) are published in the Lancet Oncol ...


Recent guidelines recommend against routine screening for prostate cancer, partly because of the risks associated with overtreatment of clinically indolent tumours. A study aimed to determine the ...


A study has analyzed the proportion of men taking Tadalafil ( Cialis ) 5 mg once-daily who reach a combined improvement ( henceforth known as a combined responder ) in symptoms of both erectile dysfun ...


Patients with metastatic renal cell carcinoma ( mRCC ) received Sunitinib ( Sutent ) in a global expanded-access program ( EAP ). Efficacy and safety results for the EAP subpopulation in Italy were r ...


Treatment with Cabozantinib ( Cometriq ) has reduced the rate of disease progression or death by 42% compared to Everolimus ( Afinitor ) in METEOR, a phase III trial comparing Cabozantinib to Everolim ...


It has been shown that increased prostate size is a risk factor for lower urinary tract symptom ( LUTS ) progression in men who currently have LUTS presumed due to benign prostatic hyperplasia ( BPH ) ...


Transurethral resection of the prostate ( TURP ) is considered gold standard for surgical treatment of benign prostatic hyperplasia ( BPH ). In this study, researchers aimed to compare post-operativ ...


A study has investigated the clinical and urodynamic features of patients with lower urinary tract symptoms/benign prostatic hyperplasia ( LUTS/BPH ) according to their prostate size. Researchers a ...


Patients with lower urinary tract symptoms ( LUTS ) have a higher prevalence of cardiovascular disease. Researchers have evaluated the correlation between LUTS and cardiovascular risk factors in men p ...